Eszopiclone + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Insomnia
Conditions
Primary Insomnia
Trial Timeline
Aug 1, 2006 → Sep 1, 2010
NCT ID
NCT00365976About Eszopiclone + Placebo
Eszopiclone + Placebo is a approved stage product being developed by Sumitomo Pharma for Primary Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT00365976. Target conditions include Primary Insomnia.
What happened to similar drugs?
20 of 20 similar drugs in Primary Insomnia were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01102270 | Phase 1 | Completed |
| NCT00645944 | Pre-clinical | Completed |
| NCT00826111 | Approved | Completed |
| NCT00414037 | Approved | Terminated |
| NCT00386334 | Approved | Completed |
| NCT00833547 | Pre-clinical | Completed |
| NCT00392041 | Approved | Completed |
| NCT00365976 | Approved | Completed |
| NCT00555750 | Pre-clinical | Completed |
| NCT00374192 | Pre-clinical | Completed |
| NCT00368056 | Phase 3 | Completed |
| NCT00368160 | Phase 1 | Completed |
| NCT00367965 | Phase 3 | Completed |
| NCT00366093 | Phase 3 | Completed |
| NCT00352144 | Phase 3 | Completed |
| NCT00685269 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Insomnia